Sugi Predict

Sugi Predict / Compounds / SCHEMBL6711422

SCHEMBL6711422

SCHEMBL6711422

NN=C(c1ccccc1)c1ccccc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSTA1 P08263 1/20 0.51
▸ HPGD P15428 6/20 0.45
▸ KDM4E B2RXH2 5/20 0.45
▸ ALDH1A1 P00352 4/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ CA12 O43570 1/20 0.45
▸ CA1 P00915 1/20 0.45
▸ CA2 P00918 1/20 0.45
▸ HMGB1 P09429 1/20 0.45
▸ CA4 P22748 1/20 0.45
▸ CA6 P23280 1/20 0.45
▸ CA7 P43166 1/20 0.45
▸ CA9 Q16790 1/20 0.45
▸ NAPRT Q6XQN6 1/20 0.45
▸ CA14 Q9ULX7 1/20 0.45
▸ CYP3A4 P08684 2/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ HSD17B10 Q99714 3/20 0.43
▸ MAPT P10636 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6711416 1.00 GSTA1 (0.51) GSTA1HPGDKDM4EALDH1A1SMN1; SMN2
SCHEMBL17548950 0.81 MGLL (0.59) GSTA1HPGDKDM4EALDH1A1SMN1; SMN2
SCHEMBL5896900 0.81 MGLL (0.59) GSTA1HPGDKDM4EALDH1A1SMN1; SMN2
SCHEMBL1141828 0.79 BLM (0.43) HPGDALDH1A1NAPRTCYP3A4HSD17B10
SCHEMBL16089348 0.79 BLM (0.43) HPGDALDH1A1NAPRTCYP3A4HSD17B10
SCHEMBL9853483 0.79 MAPT (0.53) HPGDKDM4EALDH1A1SMN1; SMN2CA1
SCHEMBL6740768 0.78 ALDH1A1 (0.45) HPGDALDH1A1SMN1; SMN2CA12CA1
SCHEMBL6740766 0.78 ALDH1A1 (0.45) HPGDALDH1A1SMN1; SMN2CA12CA1
SCHEMBL4386647 0.78 GSTA1 (0.50) GSTA1HPGDKDM4EALDH1A1SMN1; SMN2
SCHEMBL4386650 0.78 GSTA1 (0.50) GSTA1HPGDKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040053977-A1 Medicinal uses of hydrazones ALMSTEAD JI-IN KIM (US) 2004-03-18 — — US claimed
US-6660737-B2 Antihypoxic agents THE PROCTER & GAMBLE COMPANY 2003-12-09 — — US claimed
US-20030092716-A1 Medicinal uses of hydrazones THE PROCTER & GAMBLE COMPANY 2003-05-15 — — US claimed
WO-2002089809-A1 MEDICINAL USES OF HYDRAZONES AND HYDRAZINES THE PROCTER & GAMBLE COMPANY (US) 2002-11-14 — — WO claimed
US-20040053977-A1 Medicinal uses of hydrazones ALMSTEAD JI-IN KIM (US) 2004-03-18 — — US disclosed
US-6660737-B2 Antihypoxic agents THE PROCTER & GAMBLE COMPANY 2003-12-09 — — US disclosed
US-20030092716-A1 Medicinal uses of hydrazones THE PROCTER & GAMBLE COMPANY 2003-05-15 — — US disclosed
WO-2002089809-A1 MEDICINAL USES OF HYDRAZONES AND HYDRAZINES THE PROCTER & GAMBLE COMPANY (US) 2002-11-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053977-A1 Medicinal uses of hydrazones PGF, VEGFA, TEK GSTA1 405/4885HPGD 18/4885KDM4E 4483/4885
US-20030092716-A1 Medicinal uses of hydrazones EPOR, VEGFA, HIF1A GSTA1 306/4885HPGD 15/4885KDM4E 4428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.